{"filing":{"accession_number":"0000055529-26-000017","cik":"0000055529","ticker":"KEQU","company_name":"KEWAUNEE SCIENTIFIC CORP /DE/","form":"8-K","filing_date":"2026-06-23","report_date":null,"primary_document":"kequ-20260623.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/55529/000005552926000017/kequ-20260623.htm"},"events":[{"id":13273,"run_id":11782,"accession_number":"0000055529-26-000017","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing Kewaunee Scientific's financial results for fiscal year 2026 and Q4 ended April 30, 2026. The Item 2.02 filing includes a press release (Exhibit 99.1) announcing full-year sales of $281.999 million (up 17.3%), net earnings of $9.618 million, and diluted EPS of $3.22, along with detailed segment results and balance sheet metrics. This is a standard quarterly/annual earnings disclosure material to investors.","company_name":"KEWAUNEE SCIENTIFIC CORP /DE/","ticker":"KEQU","filing_date":"2026-06-23","form":"8-K","submitted_at":null,"items":[{"id":10373,"accession_number":"0000055529-26-000017","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Kewaunee Scientific's financial results for fiscal year 2026 and Q4 ended April 30, 2026. The Item 2.02 filing includes a press release (Exhibit 99.1) announcing full-year sales of $281.999 million (up 17.3%), net earnings of $9.618 million, and diluted EPS of $3.22, along with detailed segment results and balance sheet metrics. This is a standard quarterly/annual earnings disclosure material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T21:10:37.605696+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10373,"accession_number":"0000055529-26-000017","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Kewaunee Scientific's financial results for fiscal year 2026 and Q4 ended April 30, 2026. The Item 2.02 filing includes a press release (Exhibit 99.1) announcing full-year sales of $281.999 million (up 17.3%), net earnings of $9.618 million, and diluted EPS of $3.22, along with detailed segment results and balance sheet metrics. This is a standard quarterly/annual earnings disclosure material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T21:10:37.605696+00:00","company_name":"KEWAUNEE SCIENTIFIC CORP /DE/","ticker":"KEQU","filing_date":"2026-06-23"}]}